PMV Pharmaceuticals, Inc. (PMVP)
1.35
+0.01
(+0.75%)
USD |
NASDAQ |
Sep 09, 15:06
PMV Pharmaceuticals Shareholders Equity (Quarterly) : 71.50M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 71.50M |
| March 31, 2026 | 87.97M |
| December 31, 2025 | 104.71M |
| September 30, 2025 | 121.00M |
| June 30, 2025 | 140.60M |
| March 31, 2025 | 160.11M |
| December 31, 2024 | 176.08M |
| September 30, 2024 | 197.91M |
| June 30, 2024 | 214.32M |
| March 31, 2024 | 212.68M |
| December 31, 2023 | 225.69M |
| September 30, 2023 | 237.61M |
| June 30, 2023 | 217.81M |
| March 31, 2023 | 230.17M |
| Date | Value |
|---|---|
| December 31, 2022 | 246.03M |
| September 30, 2022 | 261.19M |
| June 30, 2022 | 276.97M |
| March 31, 2022 | 291.84M |
| December 31, 2021 | 308.56M |
| September 30, 2021 | 324.95M |
| June 30, 2021 | 337.85M |
| March 31, 2021 | 348.30M |
| December 31, 2020 | 359.12M |
| September 30, 2020 | 368.97M |
| June 30, 2020 | -85.01M |
| March 31, 2020 | |
| December 31, 2019 | -70.47M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 1.307B |
| Alnylam Pharmaceuticals, Inc. | 1.354B |
| Anika Therapeutics, Inc. | 137.28M |
| Savara, Inc. | 143.66M |
| Vericel Corp. | 370.04M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 82.07M |
| Total Liabilities (Quarterly) | 10.57M |
| Debt to Equity Ratio | 0.003 |
| Current Ratio | 7.703 |
| Net Debt Paydown Yield | 0.25% |